Evidence is mixed regarding the effects of hematopoietic cell transplantation (HCT) on changes in cognitive functioning among adults. Meta-analysis, which is designed to help reconcile conflicting findings, has not yet been conducted on studies of adults receiving HCT. To fill this gap, the current study provides a systematic review and meta-analysis of cognitive functioning in adults receiving HCT. A search of PubMed, PsycInfo, CINAHL, and Cochrane Library yielded 732 abstracts, which were independently evaluated by pairs of raters. Seventeen studies were systematically reviewed; 11 were retained for meta-analysis. There was agreement that cognitive impairments are evident for a subset of patients before HCT. Meta-analytical findings of 404 patients revealed no significant changes in cognitive functioning pre-to post HCT (P-values 40.05). Age, time since transplant and TBI were not associated with changes in cognitive functioning. Patients who received autologous transplants were more likely to demonstrate improvements in attention (P ¼ 0.004). The systematic review identified several limitations of existing literature, including small, clinically heterogeneous samples. Large, cooperative group studies are needed to address these design limitations. Nevertheless, results from the current meta-analysis suggest that cognitive functioning does not significantly change following HCT.
INTRODUCTION
Advances in hematopoietic cell transplant (HCT) have resulted in its increasing use in recent years, giving rise to a growing number of HCT survivors. 1 Nevertheless, HCT remains a physically demanding treatment that may result in neurotoxicities such as delirium, seizures and risk of significant cognitive impairment. [2] [3] [4] Impairment in cognitive function can have important consequences for quality of life, such as the ability to return to work or school, function socially and attain career and educational goals. 5, 6 Subjective reports of cognitive impairments are common before and after HCT. HCT patients often report difficulties in concentration, memory and word-finding. [7] [8] [9] Nevertheless, studies of objective neuropsychological functioning in HCT patients show mixed findings. A number of studies have reported that some patients experience impaired functioning on neuropsychological tests before HCT, but there are inconsistencies in the literature regarding whether cognitive functioning improves, declines or remains stable following transplant. Meta-analysis is an ideal technique to help reconcile conflicting data, in which a weighted average of effect sizes is calculated across studies. By pooling samples across studies, there is increased power to find effects where they exist.
The objective of the current systematic review and metaanalysis was to evaluate studies of cognitive functioning in adults undergoing HCT for hematological malignancies. We sought to identify all studies that assessed adults with hematological cancers pre-and post transplant using neuropsychological tests. We hypothesized there would be significant declines in cognitive functioning at follow-up compared with baseline. We also aimed to explore the effects of demographic and clinical factors on changes in cognitive functioning.
MATERIALS AND METHODS

Search strategy
This systematic review and meta-analysis was conducted in accordance to PRISMA guidelines. 10 Identification of appropriate studies began with searches of PubMed, PsycInfo, Cumulative Index to Nursing and Allied Health Literature (CINAHL) and the Cochrane Library. Search terms are presented in Table 1 . Reference lists from publications retrieved were also examined to identify studies. The search was inclusive of studies published up to September 2011 with no limit on start date.
Selection strategy
Selection of abstracts for full review was conducted by three pairs of raters. Abstracts were independently rated and each rater generated a list of studies to retrieve for full-text review. Lists were then compared and discrepancies resolved by consensus. Study inclusion criteria are shown in Table 2 .
Review strategy
Studies selected for full-text review were examined and data were extracted independently by pairs of raters. Discrepancies in data extraction were resolved by consensus. Abstraction of results focused on the baseline assessment closest to the time of transplant and the last post-transplant follow-up. Data extracted included neuropsychological test data (that is, means, s.ds., sample size), study design characteristics (that is, timing of assessments), patient characteristics (that is, age and education) and treatment characteristics (that is, transplant type, time since HCT, and treatment with TBI, intrathecal chemotherapy and cranial irradiation). When published articles did not present sufficient data to calculate effect sizes, authors were contacted for the required information.
Neuropsychological domains
Neuropsychological tests were categorized according to the predominant cognitive domain they assessed. 11 The eight domains were: attention, executive functioning, information processing, motor speed, verbal ability, verbal memory, visual memory, and visuospatial ability. 11 Neuropsychological tests and their corresponding cognitive domains are provided in Supplementary Table S1 .
Statistical analysis
Meta-analytic procedures were based on those outlined by Hedges and Olkin. 12 Where studies presented separate means and s.ds. for patients who did and did not have delirium, 6, 13 the data for these two groups were pooled. Individual effect size estimates were computed for each reported neuropsychological test. The information used to generate effect size estimates (g) was based upon within-subjects change from pre-HCT baseline to the last post-HCT measurement point. Random effects models were used to calculate effect sizes. 14 In addition to describing the differences between pre-and post-HCT cognitive functioning, we identified a priori several moderating characteristics that could potentially impact effect sizes. Age, education, time post HCT and percentage of patients receiving autologous SCT, TBI, intrathecal chemotherapy and cranial irradiation were identified for examination as continuous moderators using meta-regression with method of moments estimation. Meta-regression was only performed for cognitive domains that contained at least five studies. Analyses were conducted using Comprehensive Meta Analysis software version 2.2.057.
RESULTS
Search results
Of a total of 732 abstracts identified through searches of electronic databases, 17 studies met criteria for systematic review 6, 13, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] (see Figure 1 ). Regarding the meta-analysis, although 13 studies assessed patients at both pre-HCT and post HCT using standardized neuropsychological assessments, sufficient data to calculate effect sizes were not available for two studies. 22, 23 Study characteristics of the 11 studies retained for metaanalysis 6, 13, 20, 21, [24] [25] [26] [27] [28] [29] [30] and the additional six studies included in the review [16] [17] [18] [19] 22, 23 are displayed in Table 3 .
Description of study participants
Demographic and clinical characteristics of participants in the 17 studies are presented in Table 3 . Sample sizes for pre-HCT assessments ranged from 14 to 286. Sample sizes for the last post-HCT assessments ranged from 9 to 83. All studies consisted of samples that included both men and women. All studies reported age; average age ranged from 35.50 to 53.05 years (median ¼ 42.59 years). Of the studies that reported years of education as a continuous variable (k ¼ 6), 6, 13, 18, 22, 24, 26 average education ranged from 9.90 to 15.25 years (median ¼ 14.53 years); the study with an average of 9.90 years of education 18 included patients as young as 16 years old, who were likely still in school.
As shown in Table 3 , studies included patients with variety of hematological malignancies, including lymphoma, leukemia and/ or multiple myeloma. Some studies also included a subset of patients with non-hematological malignancies (for example, breast carcinoma, severe aplastic anemia). Four studies contained only participants who received an allogeneic transplant, 21, 23, 25, 29 three studies contained only participants who received an autologous transplant, 18, 20, 30 and nine studies contained both, with the percentage of patients receiving autologous transplants ranging from 12.5% to 58%. 6, 13, 17, 19, 22, 24, [26] [27] [28] One study did not report type of transplant. 16 Studies varied in their reporting of induction regimens. The percentage of patients who received TBI ranged from 1.8% to 100% (k ¼ 14) 6, [16] [17] [18] [19] [20] [21] 23, [25] [26] [27] [28] [29] [30] and was not reported in three studies. 13, 22, 24 Of the studies that included patients who had received cranial irradiation (k ¼ 5), percentages ranged from 2.5% to 14.5%. [16] [17] [18] [19] 23 Patients receiving cranial irradiation were excluded in five studies 25, [27] [28] [29] [30] and were not reported in five studies. 13, 21, 22, 24, 26 The remaining two studies reported one number for the percentage of patients who received cranial irradiation or intrathecal chemotherapy. 6, 20 Regarding intrathecal chemotherapy, studies were evenly split between excluding these patients, 18, 21, 25, 29, 30 including small numbers of them (8-27.3%) 16, 17, 19, 27, 28 and not reporting whether they were included. 13, [22] [23] [24] 26 Characteristics of study designs Information on the timing of assessments for the 17 studies is presented in Table 3 . Of the 17 studies, two were cross-sectional: one study included only a pre-HCT assessment 16 and one included only a post-HCT assessment. 17 Of the 15 longitudinal studies, information on baseline and last assessments are shown in Table 3 . Two longitudinal studies did not assess patients pre-and post HCT and so were not included in the meta-analysis. 18, 19 Two additional studies 22,23 did not provide sufficient data to include in the meta-analysis, resulting in a final sample of 11 studies for the meta-analysis. 6, 13, 20, 21, [24] [25] [26] [27] [28] [29] [30] Median time to last follow-up assessment in the 15 longitudinal studies ranged from during hospitalization to 8.80 years post Reviews, commentaries and case reports were excluded.
Patients had completed pre-and post-transplant assessments
Data to calculate effect sizes (that is, means and s.ds. or s.e.) must have been available or provided upon request.
Abbreviation: HCT ¼ hematopoietic cell transplantation. Table 1 ). However, median time to follow-up should be interpreted with caution because the measurement of time from HCT to follow-up varied across studies. That is, follow-up assessments were reported as time post HCT (k ¼ 9), 6, 13, [20] [21] [22] [23] [24] 26, 29 post baseline (k ¼ 2), 25,28 post last treatment 19 or post TBI (k ¼ 2). 18, 30 For one study, it was unclear whether follow-up time was post HCT or post baseline. 27 The majority of studies (71%, k ¼ 12) did not contain a comparison group. 6, 16, 17, 19, 20, [22] [23] [24] 26, 27, 29, 30 The comparison groups that were used (k ¼ 5) were heterogeneous: cancer patients who had undergone other treatments (k ¼ 2), 25, 28 people with no history of cancer (k ¼ 2) 13, 21 and people with renal insufficiency (k ¼ 1). 18 Due to heterogeneity, comparison groups were not included in the meta-analysis.
Prevalence of cognitive impairment pre-HCT As nearly all patients receive cancer treatments before their candidacy for HCT, it is likely that cognitive functioning may be impaired before transplant. The majority of studies (k ¼ 10) evaluated the percentage of patients who were cognitively impaired on neuropsychological tests before transplant. 16, 18, [22] [23] [24] 26, 27, 29, 31, 32 However, criteria for impairment varied widely. Despite differences in how it was defined, the majority of studies reported impairments in at least one domain of cognitive functioning pre-HCT. The study that found the highest rates of impairment (89% for measures of motor speed) used the most lenient criteria of z-scorespÀ1 s.d. below normative means. 22 The study that found the lowest rates of impairment (12% of patients having impaired scores on 420% of the neuropsychological tests) used the most stringent criteria of z-scorespÀ1.5 s.d. below normative means on at least four subtests. 32 Deficits in pre-HCT functioning were reported in the domains of verbal memory (k ¼ 5), 16, 24, 26, 29, 31 executive functioning (k ¼ 4), 23, 24, 26, 27 24, 26, 29 22, 27, 32 verbal ability (k ¼ 3), 18,23,31 visual memory (k ¼ 2) 18,32 and visuospatial skills (k ¼ 1). 32 Thus, there was consensus that cognitive impairment is evident before HCT, although rates of cognitive impairment varied widely.
Changes in cognitive functioning
The longitudinal studies report a mix of significant changes and no changes across neuropsychological domains. Findings were mixed regarding whether patients demonstrated improvements (k ¼ 4), 22, 24, 27, 30 20, 26, 29 both improvements and declines (k ¼ 3) 21, 23, 25 or no change (k ¼ 1) 28 on neuropsychological tests. Of the studies that found improvements in one or more domains, [21] [22] [23] [24] [25] 27, 30 improvements were observed in tests of attention, 24, 30 executive functioning, 21, 24, 30 verbal ability, 21 and visual or verbal memory. 24, 25, 27, 30 One study 22 found improvements in all the domains they assessed except attention. Of the studies that found declines 20, 23, 25, 26, 29 or persistent deficits 21, 28 in one or more domain, domains affected were 20 and verbal memory. 26 Such inconsistencies in the existing literature support the need for meta-analysis.
Meta-analytical findings
The meta-analysis is based on a final sample of 404 patients who had pre-and post-treatment neuropsychological assessments. Weighted average effect sizes for each cognitive domain are shown in Table 4 . There were no significant changes in any domain, including executive functioning (k ¼ 11), attention (k ¼ 10), verbal ability (k ¼ 10), verbal memory (k ¼ 8), motor speed (k ¼ 4), visual memory (k ¼ 3), visuospatial ability (k ¼ 3) or information processing (k ¼ 2), P-values 40.05. Meta-regression was used to determine whether effect sizes varied systematically across level of continuous variables. Domains with X5 studies (that is, executive functioning, attention, verbal ability and verbal memory) were evaluated. Results indicated that studies with a higher percentage of patients who received autologous SCTs had greater improvement over time in attention scores (b ¼ 1.58, P ¼ 0.004). There were no significant effects of age, number of days post HCT or percentage of patients who received TBI (P-values 40.05) on any of the domains. The paucity of studies that reported average years of education (k ¼ 5) or included participants who received intrathecal chemotherapy (k ¼ 2), cranial irradiation (k ¼ 1) or did not specify which of these treatments patients received (k ¼ 2) prohibited meaningful analysis of these potential moderators.
DISCUSSION
We identified 17 studies that evaluated adults receiving HCT with neuropsychological tests. Our systematic review revealed that studies varied widely with regard to demographic and clinical variables reported and how cognitive impairment was defined.
There was general consensus that cognitive impairments are evident in a subset of patients before HCT. However, there were conflicting reports about whether cognitive functioning improved, declined or remained stable at follow-up. We therefore conducted a meta-analysis based on 11 studies that had means and s.ds. available for pre-and post-transplant assessments. Results of the meta-analysis indicated no significant within-patient changes in cognitive functioning pre-to post transplant.
Regarding rates of pre-HCT cognitive impairment, the review identified 10 studies that reported the percentage of patients who demonstrated cognitive impairment. These percentages ranged from 12% to 89%, depending on how impairment was defined. These discrepant results underscore the importance of determining a standard criterion for cognitive impairment in cancer patients, such as that proposed by the International Cancer and Cognition Task Force (that is, X2 tests at or below À 1.5 s.d. from the normative mean or X1 tests at or below À 2.0 s.d. from the mean). 33 Despite differing criteria for impairment, there was With regard to pre-to post-HCT changes in functioning, the review found inconsistencies regarding whether patients declined, improved or remained stable over time and which domains of cognitive functioning were affected. The meta-analysis found trends toward improvement in verbal memory and visual memory (P-values o0.10) but no statistically significant change over time in any of the eight cognitive domains. The lack of significant change over time is contrary to our hypothesis that HCT would be associated with declines in cognitive functioning. Nevertheless, lack of pre-to post-treatment change is notable because practice effects, or improvement due to familiarity with neuropsychological tests, are typically expected upon repeated cognitive testing. The failure of HCT patients to demonstrate improvements over repeated tests may itself be a sign of a deficit. It should be noted that patients have typically been treated with X1 rounds of standard-dose chemotherapy before transplant, which may contribute to pre-HCT impairment as well as a lack of practice effects observed in this sample. The issue of practice effects underscores the importance of including matched non-cancer control groups in longitudinal studies of cognitive functioning to contrast normal expected improvement to patient change.
The general lack of significant improvement from pre-to post HCT demonstrated by the current meta-analysis is an important finding given that many patients experienced deficits before HCT. It may be the case that cognitive functioning is impaired before HCT, with minimal recovery or decline thereafter. It may also be the case that cognitive functioning declines for a subset of patients during the acute recovery period but later returns to baseline levels. The results of the current study suggest that for patients who are experiencing cognitive difficulties before HCT, it is likely that they will not significantly improve post transplant. Nevertheless, it should be noted that the median time to last follow-up was 360 days; it may be that cognitive functioning improves significantly over a longer period of time. 21 Using moderator analyses, the current meta-analysis examined the question of whether patient sociodemographic or clinical characteristics were predictive of change in cognitive functioning. Meta-regression analyses were conducted on age, time since HCT, transplant type and TBI. Of these, only transplant type was predictive of change; studies with a higher percentage of participants receiving autologous HCT reported larger improvements in attention. This difference may occur because autologous patients do not routinely receive corticosteroids, which have been associated with worse cognitive functioning 23, 31 and show evidence of neurotoxicity in animal studies. 34 It is somewhat surprising that age was not significantly associated with change in cognition, as older cancer patients are more likely to demonstrate cognitive impairments. 35 Nevertheless, patients included in the meta-analysis tended to be young (median age of 42 years) and thus may not have been as vulnerable to the negative effects of age on cognitive recovery.
The quality of a meta-analysis depends upon the quality of the studies analyzed. Studies included in the current meta-analysis are characterized by several strengths, such as the use of well-known and well-validated tests of cognitive function and longitudinal comparisons to a pre-HCT baseline. Nevertheless, limitations are evident in the existing literature. One limitation is the lack of wellmatched control groups. There were only two studies eligible for inclusion in the meta-analysis that provided a healthy comparison group 13, 21 and three studies with control patients who did not receive HCT (that is, control patients receiving imatinib mesylate, hyroxyurea or IFN, 25 non-myeloablative cancer treatments 28 or diagnosed with renal insufficiency 18 ). It can be difficult to identify an appropriate control sample of cancer patients due to adverse or poorly understood effects of other cancer treatments on cognition. Control samples of individuals without cancer, or multiple control samples, may be more appropriate. 33 Ideally, control groups should be matched to patients on age, education and gender. Another limitation is that studies were characterized by small, heterogeneous samples of HCT patients. The largest sample in the current review had 286 patients, 22 and studies commonly reported on samples with a mix of cancer diagnoses, conditioning regimens and transplant types. Study heterogeneity has resulted in limited power to examine potentially important predictors of cognitive change, such as severity of GVHD and history of intensive chemotherapy before HCT, although more recent, higher-quality studies are starting to examine these questions. 36 Similarly, recent studies are starting to examine impaired cognition as one aspect of a constellation of negative psychosocial effects of HCT. 37, 38 Cooperative group studies have been suggested to address design limitations and increase statistical power. 33 Cooperative transplant research groups such as the Blood and Marrow Clinical Trials Network and the Center for International Blood and Marrow Transplant Research are ideal for conducting these types of large studies. Thus, although there are significant limitations in existing literature, there is also an excellent HCT research infrastructure in place to support large, high-quality future studies.
Clinically, our findings suggest that patients considering HCT should be informed that, on average, they can expect post-HCT cognitive functioning to be similar to that before HCT. However, there may be subgroups of patients, such as those who receive autologous HCT, who are more likely to experience cognitive improvement. Patients reporting cognitive difficulties that interfere with daily functioning should be referred to a neuropsychologist for evaluation and management of cognitive deficits. Although research on a group-based neuropsychological training program found that it does not produce significant improvements in cognitive functioning post HCT, 19 individual therapy to learn compensatory strategies has been recommended. 19 Pharmacological treatments, such as modafinil, may also be tried. 39 Additional research is needed to identify patients at risk for clinically significant cognitive impairment and to develop effective management strategies to help them achieve the best possible cognitive outcomes.
